ProtoKinetix has formulated a proprietary anti-aging glycopeptide with the potential to change lives through cell survival. The possibilities are endless, and we’ve only seen the tip of the iceberg.
Discovery2002Dr. Geraldine Castelot-Deliencourt invented AAGP® to be a smaller, more stable synthetic version of naturally occurring anti-freeze glycopeptides (AFGPs).
Patenting2004 to 2017ProtoKinetix filed patents for the use of AAGP® in clinical studies, including biologic material preservation, cryosurgery, pancreatic cell health and neurosensory precursor cell survival.
Research2016 to presentA team of the world’s top scientists are studying AAGP®’s safety and effectiveness in cell cryopreservation, monoclonal antibody production and retinal cell replacement over time.
Results2016 to presentCompared to control groups, pluripotent stem cells treated with AAGP® were 300% more viable when transplanted into retinal tissue and matured to the five-month milestone without compromise.
Invest in the future
If you could help find a cure for chronic conditions that affect our lives, what would that be worth to you? An investment in ProtoKinetix is an investment in your financial future and the future of health care. AAGP® could be used in multi-billion-dollar applications, touching millions of lives – starting with yours.
- Chronic dry eye disease
- Diabetic retinopathy
- Macular degeneration
- Sjogren’s syndrome
Ready to invest or just want to talk?
Create a secure online account
Sign up to review research reports and company information not yet released to the general public.
Find answers in our investor FAQ
Find answers to our most commonly asked questions or submit your own.
Join us on our journey of cell survival
Get company news and research updates sent directly to your inbox.
Reach out and let’s talk about how we can help each other.